Quarterly Financial Data (unaudited) - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of Collaborative Arrangement Agreements [Line Items]
Product revenues, net	$ 1,413,265	$ 949,828	$ 941,293	$ 858,435	$ 870,106	$ 784,535	$ 752,157	$ 640,799	$ 4,162,821	$ 3,047,597	$ 2,488,652
Income tax (benefit) resulting in the release of valuation allowance					(1,560,000)
ORKAMBI
Schedule of Collaborative Arrangement Agreements [Line Items]
Product revenues, net	$ 155,800
CRISPR Therapeutics
Schedule of Collaborative Arrangement Agreements [Line Items]
Collaborative arrangement, development and commercialization rights potential maximum milestone payments		$ 175,000
Merck KGaA and Arbor
Schedule of Collaborative Arrangement Agreements [Line Items]
Collaborative arrangement, development and commercialization rights potential maximum milestone payments					$ 95,000